譽衡藥業(002437.SZ):2017年度第二期中期票據兑付完成
格隆匯3月2日丨譽衡藥業(002437.SZ)公佈,公司於2017年2月24日發行了2017年度第二期中期票據(債券簡稱:17譽衡藥業MTN002,債券代碼:101783003),發行總額為人民幣5億元,發行利率為5.30%,期限3+2年。該債券設有發行人利率調整選擇權和投資者回售選擇權,行權日為2020年2月28日。2020年2月14日為回售申請截止日,回售結果為全額回售,公司應於2020年2月28日完成本期中期票據的本金及利息兑付。
2020年2月28日,公司完成了該期中期票據的兑付,兑付本金總額為人民幣5億元,兑付最後一個年度利息總額為人民幣2650萬元。
截止目前,公司於2017年發行的第一期中期票據(17譽衡藥業MTN001)及第二期中期票據(17譽衡藥業MTN002)的本金及利息已經全部償還。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.